Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report

Rik J. L. van der Lans; Erik van Spronsen; Wytske J. Fokkens; Sietze Reitsma

doi:https://doi.org/10.1002/lary.29730

Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report

Rik J. L. van der Lans, Erik van Spronsen, Wytske J. Fokkens, Sietze Reitsma

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media (OM) characterized by eosinophilic accumulation in the middle ear mucosa and secretion. Associated sensorineural hearing loss can eventually lead to (functional) deafness. EOM is strongly associated with type 2 inflammation driven respiratory disease, i.e. asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), for which biological treatment is available. This case report discusses a patient suffering from EOM with severe mixed hearing loss, nearing functional deafness. Dupilumab treatment resulted in complete and enduring remission of the EOM, enabling adequate hearing rehabilitation. Concurrent control of the comorbid asthma and CRSwNP was obtained. Laryngoscope, 131:2649–2651, 2021.

Original language	English
Pages (from-to)	2649-2651
Number of pages	3
Journal	Laryngoscope
Volume	131
Issue number	12
Early online date	2021
DOIs	https://doi.org/10.1002/lary.29730
Publication status	Published - Dec 2021

Keywords

Biological
dupilumab
eosinophilic otitis media
human monoclonal antibody

Access to Document

https://doi.org/10.1002/lary.29730

Cite this

@article{af8747ecb9e2481d9de0639e1685a5f4,

title = "Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report",

abstract = "Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media (OM) characterized by eosinophilic accumulation in the middle ear mucosa and secretion. Associated sensorineural hearing loss can eventually lead to (functional) deafness. EOM is strongly associated with type 2 inflammation driven respiratory disease, i.e. asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), for which biological treatment is available. This case report discusses a patient suffering from EOM with severe mixed hearing loss, nearing functional deafness. Dupilumab treatment resulted in complete and enduring remission of the EOM, enabling adequate hearing rehabilitation. Concurrent control of the comorbid asthma and CRSwNP was obtained. Laryngoscope, 131:2649–2651, 2021.",

keywords = "Biological, dupilumab, eosinophilic otitis media, human monoclonal antibody",

author = "{van der Lans}, {Rik J. L.} and {van Spronsen}, Erik and Fokkens, {Wytske J.} and Sietze Reitsma",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.",

year = "2021",

month = dec,

doi = "https://doi.org/10.1002/lary.29730",

language = "English",

volume = "131",

pages = "2649--2651",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report

AU - van der Lans, Rik J. L.

AU - van Spronsen, Erik

AU - Fokkens, Wytske J.

AU - Reitsma, Sietze

PY - 2021/12

Y1 - 2021/12

N2 - Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media (OM) characterized by eosinophilic accumulation in the middle ear mucosa and secretion. Associated sensorineural hearing loss can eventually lead to (functional) deafness. EOM is strongly associated with type 2 inflammation driven respiratory disease, i.e. asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), for which biological treatment is available. This case report discusses a patient suffering from EOM with severe mixed hearing loss, nearing functional deafness. Dupilumab treatment resulted in complete and enduring remission of the EOM, enabling adequate hearing rehabilitation. Concurrent control of the comorbid asthma and CRSwNP was obtained. Laryngoscope, 131:2649–2651, 2021.

AB - Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media (OM) characterized by eosinophilic accumulation in the middle ear mucosa and secretion. Associated sensorineural hearing loss can eventually lead to (functional) deafness. EOM is strongly associated with type 2 inflammation driven respiratory disease, i.e. asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), for which biological treatment is available. This case report discusses a patient suffering from EOM with severe mixed hearing loss, nearing functional deafness. Dupilumab treatment resulted in complete and enduring remission of the EOM, enabling adequate hearing rehabilitation. Concurrent control of the comorbid asthma and CRSwNP was obtained. Laryngoscope, 131:2649–2651, 2021.

KW - Biological

KW - dupilumab

KW - eosinophilic otitis media

KW - human monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85109085858&partnerID=8YFLogxK

U2 - https://doi.org/10.1002/lary.29730

DO - https://doi.org/10.1002/lary.29730

M3 - Article

C2 - 34216146

SN - 0023-852X

VL - 131

SP - 2649

EP - 2651

JO - Laryngoscope

JF - Laryngoscope

IS - 12

ER -

Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report

Abstract

Keywords

Access to Document

Other files and links

Cite this